In addition to the benefits of the newer medications for reducing severe hypoglycemia, as well as cardiovascular and renal morbidity and mortality, our study also accounted for the potential side effects associated with GLP-1 receptor agonists and SGLT-2 inhibitors, such as gastrointestinal issues, pancreatitis, urogenital infections, and ketoacidosis. The gene discussed is SLC5A2; the disease is Hypoglycemia.